Terms: = Gastric cancer AND RHOH, TTF, 399, ENSG00000168421, ARHH, RhoH AND Clinical Outcome
4 results:
1. Decreased expression of IDH1-R132H correlates with poor survival in gastrointestinal cancer.
Li J; Huang J; Huang F; Jin Q; Zhu H; Wang X; Chen M
Oncotarget; 2016 Nov; 7(45):73638-73650. PubMed ID: 27655638
[TBL] [Abstract] [Full Text] [Related]
2. Pre-adjuvant chemotherapy leukocyte count may predict the outcome for advanced gastric cancer after radical resection.
Pei D; Zhu F; Chen X; Qian J; He S; Qian Y; Shen H; Liu Y; Xu J; Shu Y
Biomed Pharmacother; 2014 Mar; 68(2):213-7. PubMed ID: 24581723
[TBL] [Abstract] [Full Text] [Related]
3. Genetic polymorphisms of ERCC1‑118, XRCC1‑399 and GSTP1‑105 are associated with the clinical outcome of gastric cancer patients receiving oxaliplatin‑based adjuvant chemotherapy.
Liu YP; Ling Y; Qi QF; Zhang YP; Zhang CS; Zhu CT; Wang MH; Pan YD
Mol Med Rep; 2013 Jun; 7(6):1904-11. PubMed ID: 23604281
[TBL] [Abstract] [Full Text] [Related]
4. Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy.
Huang ZH; Hua D; Du X
Cancer Chemother Pharmacol; 2009 Oct; 64(5):1001-7. PubMed ID: 19247656
[TBL] [Abstract] [Full Text] [Related]
